Prima BioMed, which reported a $A287,000 operating cash loss for the March 2009 quarter, may soon announce it has secured new funding. Specifically, small-capitalization US fund manager, SpringTree Capital, has reportedly provided the Australian-listed group with $A25.5m via a convertible note facility. Prima's CVac product will soon undergo phase II clinical trials. Pfizer will oversee the US approval process for the product
Prima BioMed, which reported a $A287,000 operating cash loss for...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.010(2.70%) |
Mkt cap ! $551.9M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 39.0¢ | 37.0¢ | $1.296M | 3.401M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54900 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 22008 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |